Study S000079

The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06489457
Acronym: SEMAT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 25
Start: 2020-09-20
Primary completion: 2023-05-11
Lead sponsor: University Medical Centre Ljubljana
Conditions: Type 2 Diabetes Mellitus; Obesity; Functional Hypogonadism
Interventions: DRUG:Semaglutide; DRUG:Testosterone Undecanoate
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:0120-26/2020/13

Registered primary outcomes

Change in semen volume from baseline and between the treatment arms [Baseline and 24 weeks]
Change in sperm concentration from baseline and between the treatment arms [Baseline and 24 weeks]
Change in total motility of sperm from baseline and between the treatment arms [Baseline and 24 weeks]
Change in normal sperm forms from baseline and between the treatment arms [Baseline and 24 weeks]
Change in total number of sperm from baseline and between the treatment arms [Baseline and 24 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0019948	Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. Gregorič N, Diabetes, obesity & metabolism	2025	Randomized trial	PMID 39511836 DOI	cites ClinicalTrials.gov:NCT06489457; registry reference DERIVED:39511836